scholarly journals Haematological abnormalities and pharmacotherapy in severe acute respiratory syndrome corona virus 2

2021 ◽  
Vol 10 (7) ◽  
pp. 855
Author(s):  
Latesh B. Raghute ◽  
Sujata Dudhgaonkar ◽  
Pravin S. Uike ◽  
Kavita M. Jaiswal
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Ventilatory Support ◽  
Supplemental Oxygen ◽  
Reactive Protein ◽  
Treatment And Prevention ◽  
Corona Virus ◽  
First Case ◽  
Risk Patients ◽  
Hematological Manifestations ◽  
Loss Of Appetite

The first case of SARS-CoV-2 (severe acute respiratory syndrome corona virus 2) was reported in Wuhan, China at the end of year 2019. It shows flu-like symptoms, but anosmia, fatigue, persistent cough and loss of appetite, that collectively might spot individuals with COVID-19. The aim of writing this review was to gather the information about blood abnormalities and pharmacotherapy for COVID-19 as a resource for healthcare professionals. A blood workup as well as continuous tracking hematological changes could divulge the risks of disease progression. The indirect indicators such as C-reactive protein (CRP), D-dimer, albumin, ferritin and LDH levels which are used as markers to estimate the severity of COVID-19 infection and prognosis. The most common hematological findings include lymphocytopenia, neutrophilia, eosinopenia, mild thrombocytopenia and less frequently, thrombocytosis. Clinical management includes prophylactic and therapeutic measures. Supportive care including supplemental oxygen and mechanical ventilatory support as and when indicated. Several class of drugs like anti-malarial, anti-viral, anti-inflammatory drugs are being used for the treatment and prevention of COVID-19. The target for development of most of the vaccine for COVID-19 is S protein of the corona virus. Various vaccines available for use across the globe are COVAX, Covishield, Moderna, Johnson and Johnson, Sputnik V, Novavax, Sinopharm, SinoVac. Serial monitoring of hematological manifestations is recommended and the treating doctor should stay vigilant and consider proper screening. The therapeutic intention is to decrease viral load and pharmacological thrombo-prophylaxis in high risk patients.

Novel Coronavirus Disease (COVID-19): A Narrative Review Based on Current Status

2020 ◽  
Vol 18 ◽  
Author(s):  
Rina Das ◽  
Dinesh Kumar Mehta ◽  
Meenakshi Dhanawat
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Clinical Symptoms ◽  
Virus Disease ◽  
Relevant Literature ◽  
World Health ◽  
Current Status ◽  
Future Research ◽  
Treatment And Prevention ◽  
First Case ◽  
Novel Coronavirus

Abstract:: A novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared and expanded globally by the end of year in 2019 from Wuhan, China, causing severe acute respiratory syndrome. During its initial stage, the disease was called the novel coronavirus (2019-nCoV). It was named COVID-19 by the World Health Organization (WHO) on 11 February 2020. The WHO declared worldwide the SARS-CoV-2 virus a pandemic on March 2020. On 30 January 2020 the first case of Corona Virus Disease 2019 (COVID-19) was reported in India. Now in current situation the virus is floating in almost every part of the province and rest of the globe. -: On the basis of novel published evidences, we efficiently summarized the reported work with reference to COVID-19 epidemiology, pathogen, clinical symptoms, treatment and prevention. Using several worldwide electronic scientific databases such as Pubmed, Medline, Embase, Science direct, Scopus, etc were utilized for extensive investigation of relevant literature. -: This review is written in the hope of encouraging the people successfully with the key learning points from the underway efforts to perceive and manage SARS-CoV-2, suggesting sailent points for expanding future research.

scholarly journals An overview on Severe Acute Respiratory Syndrome (SARS)

2005 ◽  
Vol 63 (3) ◽  
Author(s):  
D.S.C. Hui
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Medical Profession ◽  
Ventilatory Support ◽  
Major Complication ◽  
Supplemental Oxygen ◽  
Control Measures ◽  
Systemic Steroid ◽  
Promising Alternative ◽  
Infection Control Measures ◽  
Immune Mediated

Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease that has caught the medical profession by surprise in 2003. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea but diarrhea occurs in 40-70% of patients after hospital admission. Respiratory failure is the major complication of SARS; at least half of the patients require supplemental oxygen during the acute phase whereas about 20% of patients progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. In contrast, the severity is generally mild in infected young children. Due to our limited understanding of this new disease, treatment of SARS was empirical in 2003. Protease inhibitor (Lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase whereas nelfinavir is a promising alternative. The role of interferon and systemic steroid in preventing immune- mediated lung injury deserves further investigation. In addition, other anti-viral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. Rapid diagnosis, early isolation, and good infection control measures are important in preventing spread of the infection.

scholarly journals Neonate with Rare Clinical Presentation of COVID-19: A Report of Two Clinically Distinct Cases

2021 ◽  
Vol 7 (2) ◽  
pp. 102-106
Author(s):  
Ruma Parvin ◽  
Sharmin Afroze ◽  
AHM Khairul Bashar ◽  
Sheikh Farjana Sonia ◽  
Nobo Krishna Ghosh
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Tertiary Care ◽  
Male Infant ◽  
Detailed Examination ◽  
Medical Community ◽  
Care Hospital ◽  
Reactive Protein ◽  
First Case ◽  
Atypical Presentations ◽  
Inflammatory Syndrome

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the world. We describe two cases of neonate, presenting with features like multisystem inflammatory syndrome (MIS-C), who presented to our neonatal unit of Dr. M R Khan Shishu Hospital, Bangladesh on August, 2020.Case 1 was a 7-day-old male infant presented at 14 hours of life with fever, poor feeding, per rectal bleeding and shock. Detailed examination revealed Down’s fancies and pallor. Case 2 was 15-day old neonate presenting with fever, rash and convulsion and his laboratory values were remarkable for high levels of C-reactive protein, D-dimer, ferritin and his Cerebrospinal fluid (CSF) findings were consistent with aseptic meningitis. Both babies were tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First case was very critical and referred to tertiary care hospital after stabilization. 2nd case recovered completely and was discharged to home in 15 days. Though till date COVID 19 in neonate is not very well-known to us, it is essential to disseminate information among the medical community regarding severe and atypical presentations of COVID-19 in neonate as prior knowledge can help to quickly identify and treat these patients as they present in the neonatal department. Bangladesh Journal of Infectious Diseases 2020;7(2):102-106

scholarly journals The First Case of Reactive Arthritis Associated with SARS-CoV-2-Infection in A 4-Year Old Child

2020 ◽  
Author(s):  
Stephanie Gabriele Werner ◽  
Hans-Eckhard Langer
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Reactive Arthritis ◽  
Virus Disease ◽  
The Novel ◽  
Case Presentation ◽  
Corona Virus ◽  
First Case ◽  
Novel Coronavirus ◽  
The Right

Abstract Background: The novel coronavirus SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2) and its associated disease COVID‐19 (Corona Virus Disease 19) has become a worldwide pandemic since its first cases in December 2019 in Wuhan Province in China. In Germany the pandemic started in February 2020.Case presentation: A 4 year old boy was presented and suffered from pain in the right hip. Arthrosonography demonstrated a significant effusion in the involved joint. The extended history revealed a slight but long lasting cold before. Serological findings were inconspicuous except for positive ELISA (Enzyme-linked Immuno Sorbent Assay) - test for SARS-CoV-2. Conclusion: In conclusion we believe that we can report the first case of reactive arthritis associated with SARS-CoV-2 in children.

scholarly journals COVID-19: an Indian perspective

2020 ◽  
Vol 7 (5) ◽  
pp. 2003
Author(s):  
Prahlad Kadambi
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
Index Case ◽  
World Health ◽  
Corona Virus ◽  
First Case ◽  
The World ◽  
Health Organization ◽  
The University ◽  
Indian Perspective

Severe acute respiratory syndrome coronavirus 2 is currently spreading globally rapidly. The World Health Organization (WHO) named the virus as the 2019 novel corona virus (2019-nCoV) on January 7, 2020. On February 11th 2020, the illness associated was named as 2019 coronavirus disease (COVID-19). Subsequently, the WHO declared COVID-19 as a pandemic on 11 March 2020. The first case of COVID-19 was reported in India on 30 January 2020 in Thrissur, Kerala. This was the index case in India who tested positive after coming for a vacation. This individual was a student of the University of Wuhan. Subsequent cases were reported in Kerala. Subsequently, the number of cases in India increased to 519 as on 24th March 2020 with mortality in 7 patients as on 22nd March 2020 and 10 patients on 24th March 2020.

scholarly journals COVID-19 CORONA VIRUS PANDEMIC: Challenges and Managerial Strategies for Hospital as Isolation Center with special reference to Jagadguru Dattatray Hospital & Research Center, Indore.

2020 ◽  
Vol 4 (6) ◽  
pp. 10-14
Author(s):  
Suyog S Dekhne ◽  
Ankita Ratnaparkhi Dekhne
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Virus Disease ◽  
Health Department ◽  
Research Center ◽  
Private Hospitals ◽  
Corona Virus ◽  
First Case ◽  
The World ◽  
Managerial Strategies ◽  
Hospital Research

SARS CoV-2 i.e. Severe Acute Respiratory Syndrome Corona Virus-2 is the cause for spread of contagious COVID-19 (Corona Virus Disease-2019) in the world. According to resources, bats are the main source for SARS-CoV-2 communication, although the virus might have jumped from another transitional host to humans. COVID-19 was first diagnosed in Wuhan, China during end of December 2019 and has since increased progressively resulting in the current corona virus pandemic. The first case of COVID-19 in India was observed on 30th January 2020. Whereas the first case of COVID-19 in Indore (MP) was reported on 23rd March 2020 and since then it is increasing rapidly resulting in scores of casualties. Before the arrival of pandemic, Indore Administrative Department, Municipal Corporation, Health Department in co-operation with private hospitals were prepared to face the change. Jagadguru Dattatray Hospital & Research Center, Indore was one of the CDCP (Center for Disease Control & Prevention) and Isolation Centers in Indore. This paper highlights the challenges and strategies adopted by a hospital as an isolation center to fight against a world spread pandemic i.e. COVID-19.

scholarly journals Know the unknown fact of novel COVID -19 corona virus

2020 ◽  
Vol 9 (2) ◽  
pp. 1083-1088
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health ◽  
The Novel ◽  
Shortness Of Breath ◽  
Corona Virus ◽  
First Case ◽  
Kerala State ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Learning Points

Coronavirus disease (COVID-19) is a contagious disease triggered by the novel coronavirus. A novel coronavirus was observed as the causative agent and was subsequently termed COVID-19 by the World Health Organization (WHO). In December 2019, a disruption of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections appeared in Wuhan, Hubei Province, China and spread across China and beyond. In India, the first case of CORONA virus was reported in Kerala state on 30 January 2020. The most common symptoms of COVID-19 are fever, cough, shortness of breath, and breathing difficulties. In more severe cases infection can give rise to pneumonia, severe acute respiratory syndrome, and even death. The period within which the symptoms would appear is 1-14 days i.e. the incubation period of COVID-19. The present review highlights the types, etiology, transmission stages, manifestations, prevention, therapeutic options, learning points from outbreak, and initiative taken by Government of India (GOI) to control the spread of literary deathly disease.

scholarly journals Corona kills corona: convalescent sera option for global war against corona virus disease 2019

2020 ◽  
Vol 7 (5) ◽  
pp. 2001
Author(s):  
Babita . ◽  
Anita Punia ◽  
S. K. Jha ◽  
Mahavir Jangra
Keyword(s):  
Nucleic Acid ◽  
Severe Acute Respiratory Syndrome ◽  
Virus Disease ◽  
Hubei Province ◽  
Atypical Pneumonia ◽  
Corona Virus ◽  
First Case ◽  
Rna Genome ◽  
Global War ◽  
Nucleic Acid Tests

On December 31st, 2019 China reported first case of atypical pneumonia in Wuhan, the capital of Hubei province. The causative virus was found to be a beta coronavirus, closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV-1) from 2003 and similar to Sarbeco viruses isolated from bats. It was therefore termed SARS-CoV-2 and the disease was named corona virus disease 2019 (COVID-19). The outbreak in Wuhan expanded quickly and led to the lockdown of Wuhan and other parts of China. While the lockdown, at least temporarily, brought the situation under control in China, but SARS-CoV-2 spread globally causing a pandemic with more than 4 lakh infections and about 19000 fatalities (as of March 25, 2020). Nucleic acid tests that detect the SARS-CoV-2 RNA genome were quickly developed and are now widely employed to diagnose COVID-19.

Neuroblastoma: An Updated Review on Biology and Treatment

2020 ◽  
Vol 20 (13) ◽  
pp. 1014-1022 ◽  
Author(s):  
Suresh Mallepalli ◽  
Manoj Kumar Gupta ◽  
Ramakrishna Vadde
Keyword(s):  
Survival Rate ◽  
High Risk ◽  
Molecular Mechanisms ◽  
Definitive Treatment ◽  
Therapeutic Drug ◽  
Mycn Amplification ◽  
Dependent Manner ◽  
High Risk Patients ◽  
Treatment And Prevention ◽  
Risk Patients

Background: Neuroblastoma (NB) is the second leading extracranial solid tumors of early childhood and clinically characterized by the presence of round, small, monomorphic cells with excess nuclear pigmentation (hyperchromasia).Owing to a lack of definitive treatment against NB and less survival rate in high-risk patients, there is an urgent requirement to understand molecular mechanisms associated with NB in a better way, which in turn can be utilized for developing drugs towards the treatment of NB in human. Objectives: In this review, an approach was adopted to understand major risk factors, pathophysiology, the molecular mechanism associated with NB, and various therapeutic agents that can serve as drugs towards the treatment of NB in humans. Conclusions: Numerous genetic (e.g., MYCN amplification), perinatal, and gestational factors are responsible for developing NB. However, no definite environmental or parental exposures responsible for causing NB have been confirmed to date. Though intensive multimodal treatment approaches, namely, chemotherapy, surgery &radiation, may help in improving the survival rate in children, these approaches have several side effects and do not work efficiently in high-risk patients. However, recent studies suggested that numerous phytochemicals, namely, vincristine, and matrine have a minimal side effect in the human body and may serve as a therapeutic drug during the treatment of NB. Most of these phytochemicals work in a dose-dependent manner and hence must be prescribed very cautiously. The information discussed in the present review will be useful in the drug discovery process as well as treatment and prevention on NB in humans.

Sign in / Sign up

Export Citation Format

Share Document